ARDS [NASD]
Aridis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.93 Insider Own40.26% Shs Outstand17.70M Perf Week-41.85%
Market Cap15.91M Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float17.60M Perf Month-22.69%
Income-32.80M PEG- EPS next Q-0.41 Inst Own10.20% Short Float / Ratio0.30% / 0.07 Perf Quarter-31.72%
Sales2.90M P/S5.48 EPS this Y-54.70% Inst Trans5.25% Short Interest0.05M Perf Half Y-72.46%
Book/sh-2.02 P/B- EPS next Y73.50% ROA-165.20% Target Price6.00 Perf Year-66.15%
Cash/sh0.08 P/C8.37 EPS next 5Y- ROE134.90% 52W Range0.57 - 2.94 Perf YTD-42.35%
Dividend- P/FCF- EPS past 5Y-27.30% ROI591.40% 52W High-76.86% Beta1.12
Dividend %- Quick Ratio0.20 Sales past 5Y-7.50% Gross Margin- 52W Low18.89% ATR0.25
Employees34 Current Ratio0.20 Sales Q/Q-20.00% Oper. Margin- RSI (14)36.43 Volatility50.61% 26.56%
OptionableYes Debt/Eq- EPS Q/Q76.00% Profit Margin- Rel Volume2.06 Prev Close0.71
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume804.66K Price0.68
Recom2.30 SMA20-43.66% SMA50-35.38% SMA200-45.26% Volume1,654,909 Change-4.17%
Feb-19-20Initiated ROTH Capital Buy $18
Jan-25-23 04:05PM
Jan-17-23 04:30PM
Dec-28-22 08:30AM
Dec-12-22 08:05AM
07:00AM
07:00AM Loading…
Dec-05-22 07:00AM
Nov-30-22 07:00AM
Nov-22-22 09:10AM
Nov-21-22 07:55PM
06:30PM
Oct-12-22 12:16PM
Oct-11-22 05:32PM
11:49AM
Oct-04-22 08:00AM
Sep-27-22 09:20AM
03:37PM Loading…
Sep-26-22 03:37PM
Sep-21-22 11:39AM
Sep-19-22 12:15PM
11:58AM
Aug-16-22 05:25PM
04:15PM
Aug-10-22 10:40AM
08:30AM
Jul-01-22 10:56AM
09:55AM
Jun-30-22 11:49AM
09:00AM
Jun-03-22 08:00AM
May-16-22 05:45PM
04:05PM
06:04PM Loading…
Mar-31-22 06:04PM
Feb-17-22 11:41AM
06:45AM
Jan-27-22 06:45AM
Dec-29-21 06:05AM
Dec-21-21 02:55PM
12:10PM
07:16AM
04:11AM
Nov-15-21 10:42AM
Nov-12-21 04:45AM
Nov-10-21 08:00AM
Aug-12-21 09:00AM
Aug-03-21 03:00PM
Aug-02-21 08:00AM
Jul-26-21 08:30AM
Jul-19-21 08:30AM
Jul-13-21 12:22PM
06:41AM
Jul-12-21 04:05PM
Jun-30-21 04:04AM
Jun-09-21 09:21AM
May-11-21 04:01PM
Mar-30-21 05:49PM
Mar-26-21 08:00AM
Mar-08-21 07:30AM
Feb-23-21 07:25AM
07:21AM
05:30AM
Feb-16-21 11:56PM
Nov-24-20 05:30AM
Nov-20-20 04:05PM
Oct-27-20 04:24PM
Oct-19-20 08:30AM
Oct-14-20 05:30AM
Sep-08-20 05:30AM
Sep-04-20 01:32PM
Aug-11-20 04:05PM
Jul-15-20 08:42AM
Jun-26-20 05:30AM
Jun-22-20 05:30AM
Jun-18-20 05:30AM
Jun-15-20 05:30AM
May-12-20 04:05PM
May-07-20 12:08PM
May-04-20 05:30AM
Apr-29-20 05:30AM
Apr-15-20 02:28PM
Apr-08-20 04:59PM
Mar-06-20 04:05PM
Mar-05-20 05:30AM
Mar-04-20 05:30AM
Feb-28-20 02:15PM
Feb-18-20 05:30AM
Jan-28-20 02:56PM
Jan-17-20 05:34AM
Jan-03-20 02:44PM
Jan-02-20 08:46AM
05:30AM
Nov-13-19 04:05PM
Oct-19-19 08:47AM
Oct-11-19 05:30AM
Sep-30-19 05:30AM
Sep-27-19 05:45AM
05:30AM
Sep-08-19 04:28PM
Sep-03-19 09:18AM
05:30AM
Aug-14-19 03:40PM
Aug-12-19 04:05PM
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.